The Fifteen Dollar Arbitration: How the Final No Surprises Act IDR Operations Rule Cuts Dispute Fees, Rewires Provider & Payer...
The federal government finalized the No Surprises Act IDR operations rule, slashing the per‑party arbitration filing fee from $115 to $15. The cut reflects a massive surge in dispute volume—about 489,000 cases in the first year and over 5.1 million cumulative by early 2026—rather than a reduction in processing costs. Providers now win roughly 88% of disputes, often receiving awards exceeding 300% of the qualified payment amount. The rule also caps batch disputes, mandates standardized claim codes, and creates a permanent plan‑issuer registry, paving the way for arbitration‑as‑a‑service business models.
One Infusion. A Permanent Gene Edit. A Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and...
Verve Therapeutics reported Phase 1b Heart‑2 data for its gene‑editing LDL therapy VERVE‑102 in the New England Journal of Medicine. A single intravenous infusion achieved up to 88% PCSK9 knock‑down and a 62% reduction in LDL‑C that persisted for 18...
How The Joint Commission & CHAI Are Quietly Building A Parallel FDA For Hospital AI & Why The Governance Infrastructure...
The Joint Commission, which accredits roughly 80% of U.S. hospitals, partnered with the Coalition for Health AI (CHAI) to issue September 2025 guidance that embeds AI governance into accreditation standards. This creates a de‑facto regulatory layer that rivals the FDA...
HHS Goes All-In on ChatGPT for State Audits: What the May 2026 Generative AI Fraud Expansion and February’s CRUSH RFI...
On May 21, 2026 the U.S. Health and Human Services Department (HHS) launched an internal workflow that feeds single audit PDFs into ChatGPT and other large language models to flag chronic deficiencies and threaten funding cuts. The move builds on...
Eli Lilly’s Triple Agonist Retatrutide Hits 28.3% Mean Weight Loss in TRIUMPH-1 Phase 3, Blowing Past Tirzepatide Benchmarks & Rewriting...
Eli Lilly’s triple‑agonist retatrutide delivered a 28.3% mean body‑weight reduction (about 70 lb) after 80 weeks in the phase‑3 TRIUMPH‑1 trial, far surpassing tirzepatide’s ~22.5% peak. The 12 mg dose drove 62.5% of participants to lose at least 25% of their weight, with 27.2%...
Part I: Forus Just Raised $160M at a $1B Valuation to Become the Operational Routing Layer for Specialty Rx &...
The episode examines Forus (formerly Tandem), a New York startup that raised $160 million at a $1 billion valuation to become the operational routing layer for specialty prescription drugs. Host explains that investors are betting on healthcare orchestration— the invisible transaction network...
What Contracting with Epic for an EHR License Really Involves: License Structure, Module Pricing, Affiliate Rights, Hosting, Termination Economics, and...
Epic’s EHR License and Support Agreement is widely regarded as the most one‑sided contract in healthcare IT. The agreement outlines a tiered license structure, per‑module pricing, strict affiliate rights, mandatory hosting on Epic’s cloud, and steep termination penalties. Because Epic...
Part I: How Geotagged EVV Check-In Data Can Get Wired Into Medicaid and Medicare Managed Care Claim Edits to Reject...
The episode dissects the persistent fraud problem in home health agencies, highlighting how the recent CMS nationwide enrollment moratorium aims to curb new bad actors but does nothing for the roughly 11 agencies already in the system. It explains that...
Isomorphic Labs Pulls $2.1B Series B Led By Thrive With MGX, Temasek, And UK Sovereign AI Fund: What The Capital...
Isomorphic Labs closed a $2.1 billion Series B on May 12, 2026, led by Thrive Capital and joined by MGX, Temasek, CapitalG and the UK Sovereign AI Fund. The round brings total disclosed equity to roughly $2.7 billion and suggests a post‑money valuation of $15‑20 billion,...
Isomorphic Labs Pulls $2.1B Series B Led By Thrive With MGX, Temasek, And UK Sovereign AI Fund: What The Capital...
Isomorphic Labs announced a $2.1 billion Series B round led by Thrive, with participation from MGX, Temasek, and the UK Sovereign AI Fund. The funding backs the company’s IsoDDE AI engine for drug discovery, despite having no approved drugs or Phase 2 data....
The Hidden Rule Makers Behind Prior Auth and Claim Denials: How InterQual, MCG, HealthEdge, Zelis, Lyric, and Optum’s CES Write...
The article reveals that a handful of technology vendors—InterQual, MCG, Optum’s CES, Lyric, HealthEdge and Zelis—write the clinical criteria that drive most prior‑authorization and claim‑denial decisions. InterQual and MCG together command roughly 90% of the prior‑auth rule market, while the...
What the Six Hundred Billion Dollar MFN Headline Misses: The Best Price Carveout, the IQVIA Net Price Hole, and the...
The Council of Economic Advisers released a report projecting up to $600 billion in drug‑price savings over ten years, but the headline masks three critical flaws. First, the voluntary MFN agreements rely on the GENEROUS carve‑out that isolates supplemental rebates from...
Gene Editing Has the Science Figured Out and Now Needs an Entire Stack of New Business Models, Reimbursement Mechanics, and...
Gene editing has moved from scientific proof‑of‑concept to commercial reality, highlighted by Vertex's CASGEVY therapy earning $43 million in Q1 2026 and treating over 500 patients at a $2.2 million list price. While the science is solid, the therapy’s multi‑step delivery—spanning screening, cell...
What the Smart Money Just Bought in Healthcare and Life Sciences VC Over the Last Sixty Days
Between March 20 and April 21, 2026, venture capital poured $2.58 billion into ten healthcare and life‑sciences rounds, concentrating on companies that own scarce inputs rather than generic digital‑health apps. The biggest check was Earendil Labs' $787 million AI‑native biologics financing, followed...
The Peptide Split: How GLP-1s, Lutathera, Vosoritide, and Peptide Cancer Vaccines Are Quietly Rewriting Medicine While BPC-157, TB-500, MOTS-C, and...
Peptide therapeutics are diverging into two distinct trajectories. Clinically validated drugs such as GLP‑1 agonists, Lu‑177 radioligands, vosoritide, and emerging peptide cancer vaccines are delivering hard‑outcome data across cardiometabolic disease, oncology and rare disorders. In parallel, a booming wellness market...